MP49-19 EMP2 AS A NOVEL TARGET OF BLADDER CANCER IMMUNOTHERAPY

wujiang liu,jie jin,liqun zhou,yinglu guo

DOI: https://doi.org/10.1016/j.juro.2015.02.2814

2015-01-01

Abstract:You have accessJournal of UrologyBladder Cancer: Basic Research III1 Apr 2015MP49-19 EMP2 AS A NOVEL TARGET OF BLADDER CANCER IMMUNOTHERAPY Wujiang Liu, Jie Jin, liqun Zhou, and Yinglu Guo Wujiang LiuWujiang Liu More articles by this author , Jie JinJie Jin More articles by this author , liqun Zhouliqun Zhou More articles by this author , and Yinglu GuoYinglu Guo More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2814AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES EMP2, epithelial membrane protein 2, is supposed to be upregulated in cancer (Clin Cancer Res. 2008: 7367). Antibody targeting EMP2 shows benefit on cancer growth arrest (Mol Cancer Ther. 2014: 902). Here we investigated EMP2 expression in bladder cancer tissue and the potential for using as a target for cancer immunotherapy. METHODS 31 muscle invasive bladder cancer tissue and adjacent normal bladder tissue were collected from patient underwent cystectomy with informed consent. Protein expression of EMP2 was assayed by immmunohistochemical stain. T24, 5637 and SV-HUC-1 were used as cell lines for bladder cancer cells and normal bladder epithelium. Real-time PCR and Western-blot were performed to measure the mRNA and protein expression of EMP2. Chimeric antigen receptors of EMP2 (CARs-EMP2) were successfully constructed from multiple murine antibodies using second generation (CD28.CD3£a) signaling domains. Gamma-retroviral vector were used for carrying CAR and CD28.CD3£a sequences and subsequently for peripheral blood lymphocytes (PBL) transduction. Anti-tumor effect of T cells expressing CARs-EMP2 was assayed by cytolysis and cytokine release (IL-6, IFN-ƒ× and TNF-ƒÑ)ƒw following co-culture with target cell lines T24 and 5637. In vivo anti-tumor effect of T cells expressing anti-EMP2 CARs was tested on orthotopic mouse bladder cancer model. Tumor growth curve and tumor cell apoptosis were used to test the anti-tumor effect. RESULTS EMP2 was significantly increased in bladder tumor tissue compared to adjacent normal bladder tissue (P<0.01). The location of EMP2 is bladder cancer cell membrane. RNA and protein expression of EMP2 were more intensive in T24 and 5637 cells than that in SV-HUC-1 (P<0.05). T cells expressing CARs-EMP2 were able to lysis T24 and 5637 cells in a dose dependent manner and increase the cytokine release especially IL-6 and IFN-ƒ×ƒ|ƒnƒnCompared with T cells transfected with empty vector, adoptive transfer therapy with T cells transfected with CARs-EMP2 dramatically delay the tumor growth and increase the cancer cell apoptosis (P<0.01). CONCLUSIONS EMP2 is a potential target of bladder cancer immunological therapy. Adoptive transferring T cells expressing anti-EMP2 chimeric antigen receptors could be an alternative option to treat bladder cancer. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e610 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Wujiang Liu More articles by this author Jie Jin More articles by this author liqun Zhou More articles by this author Yinglu Guo More articles by this author Expand All Advertisement Advertisement PDF DownloadLoading ...